Alpha-Galactosidase A Replacement Therapy for Fabry Disease

Completed

Phase 2 Results N/A

Summary of Purpose

This study will determine the safety of the drug Replagal or treating patients with Fabry disease, an inherited metabolic disorder. In this disease, an enzyme called Alpha-galactosidase A, which normally breaks down a fatty substance called globotriaosylceramide (Gb3), is missing or does not function properly. The resulting accumulation of Gb3 causes problems with the kidneys, heart, nerves, and blood vessels. ...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 3 March 2008.

1 Nov 2002 8 Nov 2002 Unavailable 1 Nov 2003 1 Nov 2003 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics

Interventions

Conditions

Sponsors

Trial Design

  • Purpose: Treatment
  • Endpoint: Safety/Efficacy Study

Contacts

Not available